Drugs / inodiftagene vixteplasmid
inodiftagene vixteplasmid
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00826150 | Jun 2009 → Feb 2012 | ovarian cancer | Anchiano Therapeutics Israel Ltd. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT03719300 | Mar → Nov 2019 | urinary bladder carcinoma | Anchiano Therapeutics Israel Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT01413087 | Sep 2011 → Jan 2013 | pancreatic adenocarcinoma | Anchiano Therapeutics Israel Ltd. | Terminated | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | inodiftagene vixteplasmid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03719300 ↗ |
| Known as | BC-819 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00826150 ↗ |
| Known as | Inodiftagen vixteplasmida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594478 ↗ |
| Known as | Inodiftagene vixteplasmide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594478 ↗ |
| Action | Deplete | “The selective initiation of toxin expression results in selective tumor cell destruction via inhibition of protein synthesis selectively in the tumor cell” NCT01413087 ↗ |
| Modality | Other / unclassified | “double-stranded DNA plasmid” NCT01413087 ↗ |
| Route | Other | “DTA-H19 administered intraperitoneally (IP)” NCT00826150 ↗ |